We also provided compelling evidence that lnc4012/lnc9456 is a new bona fide target for a new small molecule HHQ16 to effectively reverse infarction-induced hypertrophy and HF by specific binding to lnc4012/lnc9456, causing its degradation, and antagonizing its action on the G3BP2/NF-κB signaling in cardiomyocyte. Here, G3BP2 is linked to infarction.